ArticleAnnals of surgical oncology2026
Clinical Implications of Metastatic Nodal Burden: Stratifying Risk in Resected N1 and N2 NSCLC.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent anatomical N staging often fails to reflect prognostic heterogeneity within N1 and N2 non-small cell lung cancer (NSCLC). We evaluated whether metastatic nodal burden, defined as the tumor deposit size, provides additional prognostic information beyond conventional staging. PATIENTS AND
methodsWe retrospectively analyzed 1495 patients with pN1 (n = 633) or pN2 (n = 862) NSCLC who underwent curative surgical resection between 2010 and 2019. Metastatic tumor deposit size was categorized as ≤ 5 mm, 5-9 mm, and ≥ 10 mm. Linearity between tumor size and overall survival (OS) or recurrence-free survival (RFS) was assessed using restricted cubic splines. Kaplan-Meier and multivariable Cox regression analyses were performed.
resultsMedian metastatic deposit size was 5 mm (interquartile range [IQR] 3-9) in pN1 and 10 mm (IQR 5.1-16) in pN2. In pN1, high-burden patients (≥ 10 mm) had significantly worse 5-year outcomes than low-burden group (OS: 60.0% versus 75.5%, hazard ratio [HR] 1.66; RFS: 42.2% versus 50.9%, HR 1.83). In pN2, burden independently predicted RFS (5-year rate: 26.2% for ≥ 10 mm versus 42.4% for < 5 mm; HR 1.72, p < 0.001). Notably, radiologically occult low-burden metastasis (< 5 mm) was prevalent (41% in pN1, 19% in pN2) and associated with favorable survival, yet frequently undetectable on standard preoperative imaging.
conclusionsMetastatic nodal burden reflects meaningful prognostic variation within pN1 and pN2 disease. These findings suggest that considering metastatic burden may help refine postoperative risk assessment and support more individualized management in surgically treated NSCLC.
Indexed as
Identifiers
42766269What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.